Published in Bone on August 27, 2009
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med (2011) 1.62
Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone (2011) 1.52
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
Osteocyte control of osteoclastogenesis. Bone (2012) 1.36
Critical role of filamin-binding LIM protein 1 (FBLP-1)/migfilin in regulation of bone remodeling. J Biol Chem (2012) 1.07
Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res (2010) 1.06
The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2012) 1.02
Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.99
Runx2 regulates endochondral ossification through control of chondrocyte proliferation and differentiation. J Bone Miner Res (2014) 0.93
Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem (2011) 0.93
Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One (2015) 0.93
Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone (2014) 0.92
Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Mol Cell Endocrinol (2011) 0.92
Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology (2014) 0.92
Control of bone resorption in mice by Schnurri-3. Proc Natl Acad Sci U S A (2012) 0.90
Transcription factor NF-κB regulates expression of pore-forming Ca2+ channel unit, Orai1, and its activator, STIM1, to control Ca2+ entry and affect cellular functions. J Biol Chem (2011) 0.87
Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures. World J Diabetes (2013) 0.86
The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocrinol (2011) 0.86
Proteasome inhibitors and bone disease. Semin Hematol (2012) 0.86
The multifaceted role of the vasculature in endochondral fracture repair. Front Endocrinol (Lausanne) (2015) 0.85
Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. Cell Metab (2017) 0.85
Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 β -induced RANKL, OPG, TNF α , and IL-6 expression in human rheumatoid synoviocyte MH7A. Clin Dev Immunol (2013) 0.84
Palmitic acid and DGAT1 deficiency enhance osteoclastogenesis, while oleic acid-induced triglyceride formation prevents it. J Bone Miner Res (2014) 0.83
Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. Genes Immun (2013) 0.82
Functions of the osteocyte network in the regulation of bone mass. Cell Tissue Res (2013) 0.82
Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. Bone (2015) 0.81
Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab (2012) 0.80
Periodontal ligament stem cells modulate root resorption of human primary teeth via Runx2 regulating RANKL/OPG system. Stem Cells Dev (2014) 0.80
RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease. Clin Dev Immunol (2013) 0.80
RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice. J Biol Chem (2016) 0.78
Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. ScientificWorldJournal (2013) 0.78
Feeding blueberry diets to young rats dose-dependently inhibits bone resorption through suppression of RANKL in stromal cells. PLoS One (2013) 0.78
Noncoding RNAs: Possible Players in the Development of Fluorosis. Biomed Res Int (2015) 0.78
Anti-Inflammatory, Anti-Osteoclastogenic and Antioxidant Effects of Malva sylvestris Extract and Fractions: In Vitro and In Vivo Studies. PLoS One (2016) 0.78
Effects of sex steroids on bones and muscles: Similarities, parallels, and putative interactions in health and disease. Bone (2015) 0.77
Systemic administration of strontium or NBD peptide ameliorates early stage cartilage degradation of mouse mandibular condyles. Osteoarthritis Cartilage (2015) 0.76
A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma. Osteoporos Int (2011) 0.75
Cell Death in Chondrocytes, Osteoblasts, and Osteocytes. Int J Mol Sci (2016) 0.75
Modulation of IL-6 induced RANKL expression in arthritic synovium by a transcription factor SOX5. Sci Rep (2016) 0.75
Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice. J Cell Biochem (2017) 0.75
Bone loss in adult offspring induced by low-dose exposure to teratogens. J Bone Miner Metab (2011) 0.75
Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin. Rheumatol Int (2013) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature (2000) 14.91
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature (1990) 8.94
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Recombineering: a powerful new tool for mouse functional genomics. Nat Rev Genet (2001) 8.35
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 7.47
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Multiple genetic loci for bone mineral density and fractures. N Engl J Med (2008) 6.35
Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome. Nat Biotechnol (1997) 6.29
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 5.38
Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 5.18
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem (1997) 4.61
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol (1995) 4.28
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif Tissue Int (1981) 3.77
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum (2000) 3.51
Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell (1997) 3.48
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med (2002) 3.34
Transforming growth factor-beta1 to the bone. Endocr Rev (2005) 3.13
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res (2003) 2.73
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology (1988) 2.60
Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A (2000) 2.41
BAC-mediated gene-dosage analysis reveals a role for Zipro1 (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin. Nat Genet (1999) 2.40
Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun (1999) 2.28
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci (2006) 2.18
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology (2004) 2.14
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet (2007) 2.04
Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem (2001) 2.02
Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol (2006) 1.99
Regulatory divergence modifies limb length between mammals. Genes Dev (2008) 1.96
Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol (2006) 1.92
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology (1999) 1.89
Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol (2006) 1.89
Expression profile of osteoblast lineage at defined stages of differentiation. J Biol Chem (2005) 1.83
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem (2002) 1.76
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest (2006) 1.75
Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem (1999) 1.75
Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone (1999) 1.66
Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci U S A (1998) 1.63
Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res (2008) 1.53
NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. Mol Cell Biol (2005) 1.52
Osteoprotegerin and rank ligand expression in prostate cancer. Urology (2001) 1.50
Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem (2006) 1.49
Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer (2007) 1.48
Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology (2007) 1.47
Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol (2001) 1.38
Visualization of alpha9 acetylcholine receptor expression in hair cells of transgenic mice containing a modified bacterial artificial chromosome. Proc Natl Acad Sci U S A (1999) 1.36
Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res (2002) 1.34
The mechanism of coupling: a role for the vasculature. Bone (2000) 1.33
CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis (2008) 1.32
Analysis of mammalian central nervous system gene expression and function using bacterial artificial chromosome-mediated transgenesis. Hum Mol Genet (2000) 1.30
Molecular regulation of osteoclast activity. Rev Endocr Metab Disord (2006) 1.26
Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol (2005) 1.25
Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res (2008) 1.25
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology (2003) 1.24
PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J Cell Biochem (2008) 1.21
Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem (2003) 1.20
Inflammatory bone destruction and osteoimmunology. J Periodontal Res (2005) 1.20
Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res (2000) 1.20
Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone (2006) 1.18
Cbfa1 does not regulate RANKL gene activity in stromal/osteoblastic cells. Bone (2002) 1.15
Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res (2005) 1.14
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res (2001) 1.13
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta (1999) 1.12
Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun (2002) 1.11
An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3. Mol Endocrinol (2008) 1.08
Commitment to the osteoblast lineage is not required for RANKL gene expression. J Biol Chem (2009) 1.05
The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res (2008) 1.03
Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol (1999) 1.02
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem (2003) 1.02
Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. Histochem Cell Biol (2005) 1.01
Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun (2000) 1.00
Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res (2000) 0.99
Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. J Cell Biochem (2006) 0.98
Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. J Cell Biochem (2004) 0.98
Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J Biol Chem (2002) 0.95
Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Endocrinology (2006) 0.92
Granulation rescue and developmental marking of juxtaglomerular cells using "piggy-BAC" recombination of the mouse ren locus. J Biol Chem (2000) 0.91
Interference with immune-cell-mediated bone resorption in periodontal disease. Periodontol 2000 (2007) 0.90
The cell surface form of colony-stimulating factor-1 is biologically active in bone in vivo. Endocrinology (2003) 0.90
15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors. J Immunol (2007) 0.90
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum (2004) 0.89
Evidence for heterogeneity of the osteoblastic phenotype determined with clonal rat bone cells established from transforming growth factor-beta-induced cell colonies grown anchorage independently in semisolid medium. Endocrinology (1989) 0.89
Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. Biochem Biophys Res Commun (2004) 0.88